Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Capri Holdings Ltd (CPRI) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance

Capri Holdings LtdTrade
Charles River Laboratories Intl. IncTrade

Price performance (Past 24H)

Key statistics

Capri Holdings Ltd vs Charles River Laboratories Intl. Inc — how do they compare? Capri Holdings Ltd trades at $15.56 (market cap $1.75B), while Charles River Laboratories Intl. Inc trades at $287.58 (market cap $13.46B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 7.7× Capri Holdings Ltd's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals.

CPRICRL
Market Cap
$1.75B$13.46B
Sector
Consumer StaplesHealth
52-Week High
$27.66$282.00
52-Week Low
$14.98$145.57
Enterprise Value
$3.03B$16.30B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Capri Holdings Ltd

Capri Holdings (CPRI) trades at $15.47, near its 52-week low, with a bearish technical outlook and recent earnings beats overshadowed by declining revenue and a net loss of $1.18 billion in 2025. The company faces challenges in its core Michael Kors brand, with revenue forecasts cut and a high debt-to-asset ratio of 28.79% as of 2025. Despite a consensus price target of $19.60, analyst sentiment is mixed, with 44% buy ratings but significant hold recommendations.

The stock's investment appeal hinges on a successful turnaround, with potential upside from margin improvements and Jimmy Choo growth, but risks include persistent revenue declines, luxury market softness, and execution uncertainties. Near-term volatility is likely as the company navigates brand revamps and inventory issues.

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.

While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.

Returns comparison

Trailing returns across standard periods

About Capri Holdings Ltd

Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.

Read more on CPRI

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL